General description
We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency".
Click here for more information.
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Specificity
Clone 1D9 is a ZooMAb® recombinant rabbit monoclonal antibody that specifically detects Mucolipin-1. It targets an epitope within 17 amino acids from the N-terminal half, cytoplasmic Domain.
Immunogen
KLH-conjugated linear peptide corresponding to 17 amino acids from the N-terminal half, cytoplasmic Domain of human Mucolipin-1.
Application
Quality Control Testing
Evaluated by Western Blotting in mouse spleen tissue lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected Mucolipin-1 in mouse spleen tissue lysate.
Tested Applications
Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected Anti-Mucolipin-1 in human kidney tissue sections.
Immunocytochemistry Analysis: A 1:1,000 dilution from a representative lot detected Mucolipin-1 in U-2 OS cells.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Target description
Mucolipin-1 (UniProt:Q9GZU1; also known as ML1, MG-2, Mucolipidin, Transient receptor potential channel mucolipin 1, TRPML1) is encoded by the MCOLN1 (also known as ML4, TRPML1) gene (Gene ID: 57192) in human. Mucolipin-1 is a member of the small family of the TRPML channels, a subgroup of the large protein family of TRP ion channels. It is a multi-pass membrane protein and functions as a non-selective cation channel. It is widely expressed in adult and fetal tissues and mostly found in vesicles, and is involved in the regulation of lysosomal trafficking. The most N-terminal extracellular/lumenal domain (referred to as I-II linker or polycystin-mucolipin domain) contributes to a structure with a four-fold rotational symmetry in a tetrameric assembly. The protruding structure formed by the I-II linkers may contain all the interaction sites with lipids and proteins in the endo- lysosomal lumen. The structure contains a central highly electronegative pore with a 14 A diameter. The pore is critical for Ca2+ and pH regulation. Mucolipin-1 aids in the transport of Ca2+ into the cytosol from the lumen, in response to the changing levels of phosphatidylinositol-3, 5-bisphosphate. It is also required for efficient uptake of large particles in macrophages in which Ca2+ release from the lysosomes triggers lysosomal exocytosis. May also play a role in phagosome-lysosome fusion. Mutations in the MCOLN1 gene is implicated in Mucolipidosis type IV (MLIV) is an autosomal recessive, neurodegenerative disorder characterized by developmental abnormalities of the brain and impaired neurological, ophthalmologic and gastric function. MLIV pathophysiology has been linked to deficiency in membrane trafficking, and organelle dynamics in the late endocytic pathway. Specifically, MLIV cells have been shown to accumulate autophagosomes, due to increased de novo autophagosome formation and due to delayed fusion of autophagosomes with late endosomes/lysosomes. MCOLN1 might also be involved with Alzheimer s disease and HIV. This ZooMAb® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Li, M., et al. (2017). Nature Structural & Molecular Biology. 24:205-213; Raychowdhury M.K., et al. (2004). Hum. Mol. Genet. 13:617-627).
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Reconstitution
300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.